BioNexus Gene Lab Statistics
Total Valuation
BGLC has a market cap or net worth of $5.52 million. The enterprise value is $1.37 million.
Important Dates
The next estimated earnings date is Friday, May 23, 2025.
| Earnings Date | May 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BGLC has 1.80 million shares outstanding. The number of shares has increased by 12.24% in one year.
| Current Share Class | 1.80M |
| Shares Outstanding | 1.80M |
| Shares Change (YoY) | +12.24% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 30.98% |
| Owned by Institutions (%) | 0.81% |
| Float | 1.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.58 |
| Forward PS | n/a |
| PB Ratio | 0.66 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.81 |
| Quick Ratio | 3.10 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -89.73 |
Financial Efficiency
Return on equity (ROE) is -17.78% and return on invested capital (ROIC) is -12.92%.
| Return on Equity (ROE) | -17.78% |
| Return on Assets (ROA) | -10.86% |
| Return on Invested Capital (ROIC) | -12.92% |
| Return on Capital Employed (ROCE) | -22.37% |
| Revenue Per Employee | $317,022 |
| Profits Per Employee | -$53,278 |
| Employee Count | 30 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 6.51 |
Taxes
In the past 12 months, BGLC has paid $3,494 in taxes.
| Income Tax | 3,494 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.10% in the last 52 weeks. The beta is 1.72, so BGLC's price volatility has been higher than the market average.
| Beta (5Y) | 1.72 |
| 52-Week Price Change | -47.10% |
| 50-Day Moving Average | 2.89 |
| 200-Day Moving Average | 3.52 |
| Relative Strength Index (RSI) | 58.25 |
| Average Volume (20 Days) | 107,005 |
Short Selling Information
The latest short interest is 50,545, so 2.81% of the outstanding shares have been sold short.
| Short Interest | 50,545 |
| Short Previous Month | 291,486 |
| Short % of Shares Out | 2.81% |
| Short % of Float | 4.08% |
| Short Ratio (days to cover) | 0.03 |
Income Statement
In the last 12 months, BGLC had revenue of $9.51 million and -$1.60 million in losses. Loss per share was -$0.90.
| Revenue | 9.51M |
| Gross Profit | 1.29M |
| Operating Income | -1.90M |
| Pretax Income | -2.64M |
| Net Income | -1.60M |
| EBITDA | -1.79M |
| EBIT | -1.90M |
| Loss Per Share | -$0.90 |
Full Income StatementBalance Sheet
The company has $4.38 million in cash and $227,731 in debt, giving a net cash position of $4.15 million or $2.31 per share.
| Cash & Cash Equivalents | 4.38M |
| Total Debt | 227,731 |
| Net Cash | 4.15M |
| Net Cash Per Share | $2.31 |
| Equity (Book Value) | 8.32M |
| Book Value Per Share | 4.63 |
| Working Capital | 5.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$2.23 million and capital expenditures -$226,989, giving a free cash flow of -$2.46 million.
| Operating Cash Flow | -2.23M |
| Capital Expenditures | -226,989 |
| Free Cash Flow | -2.46M |
| FCF Per Share | -$1.37 |
Full Cash Flow StatementMargins
Gross margin is 13.56%, with operating and profit margins of -19.95% and -16.81%.
| Gross Margin | 13.56% |
| Operating Margin | -19.95% |
| Pretax Margin | -16.77% |
| Profit Margin | -16.81% |
| EBITDA Margin | -18.85% |
| EBIT Margin | -19.95% |
| FCF Margin | n/a |